Novozymes Biopharma DK A/S — Credit Rating and Financial Key Figures
CVR number: 29603537
Krogshøjvej 36, 2880 Bagsværd
tel: 44460000
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Other operating income | 317 120.31 | 47 429.01 | 58 801.63 | 242.70 | 977.42 |
| External services | - 334.07 | - 234.77 | -81.20 | - 156.50 | -65.65 |
| Gross profit | 316 786.25 | 47 194.25 | 58 720.43 | - 399.20 | 911.76 |
| EBIT | 316 786.25 | 47 194.25 | 58 720.43 | - 399.20 | 911.76 |
| Other financial income | 2 015.18 | 4 693.83 | 4 503.08 | 2 159.76 | 18 513.26 |
| Other financial expenses | -1 246.49 | -1 035.15 | -4 422.30 | -3 453.64 | - 312.57 |
| Income from other inv. held as non-curr. assets | 1 769.48 | 6 210.40 | 267 421.22 | ||
| Pre-tax profit | 317 554.94 | 52 622.41 | 65 011.62 | 265 728.14 | 19 112.45 |
| Income taxes | -69 862.09 | -11 460.15 | -13 892.67 | 338.16 | -4 204.74 |
| Net earnings | 247 692.86 | 41 162.27 | 51 118.95 | 266 066.30 | 14 907.71 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Non-current loans receivable | 175.80 | 175.80 | 175.80 | ||
| Long term receivables total | 175.80 | 175.80 | 175.80 | ||
| Inventories total | |||||
| Current amounts owed by group member comp. | 539 345.26 | 166 234.14 | 122 260.33 | 321 861.97 | 75 316.73 |
| Current other receivables | 137.33 | 42.15 | |||
| Current deferred tax assets | 2 216.79 | 672.59 | 295.44 | 633.60 | 53.41 |
| Short term receivables total | 541 699.37 | 166 906.73 | 122 555.78 | 322 495.57 | 75 412.29 |
| Cash and bank deposits | 522.69 | 429.35 | 464.49 | 500.51 | 507.50 |
| Cash and cash equivalents | 522.69 | 429.35 | 464.49 | 500.51 | 507.50 |
| Balance sheet total (assets) | 542 397.87 | 167 511.89 | 123 196.07 | 322 996.09 | 75 919.79 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 612.00 | 612.00 | 612.00 | 612.00 | 612.00 |
| Shares repurchased | 300 000.00 | 40 000.00 | 53 000.00 | 265 000.00 | 60 000.00 |
| Retained earnings | - 192 112.90 | 15 579.95 | 3 742.22 | - 210 138.83 | -4 072.53 |
| Profit of the financial year | 247 692.86 | 41 162.27 | 51 118.95 | 266 066.30 | 14 907.71 |
| Shareholders equity total | 356 191.95 | 97 354.22 | 108 473.16 | 321 539.47 | 71 447.18 |
| Provisions | 104 544.59 | 56 699.14 | |||
| Non-current liabilities total | |||||
| Current trade creditors | 62.56 | 62.50 | 62.56 | 77.50 | |
| Current owed to group member | 685.31 | 148.44 | 121.88 | 133.14 | |
| Short-term deferred tax liabilities | 72 056.49 | 9 915.95 | 13 515.52 | 4 043.37 | |
| Other non-interest bearing current liabilities | 8 856.97 | 3 331.64 | 1 144.83 | 1 334.74 | 218.60 |
| Current liabilities total | 81 661.33 | 13 458.53 | 14 722.91 | 1 456.62 | 4 472.61 |
| Balance sheet total (liabilities) | 542 397.87 | 167 511.89 | 123 196.07 | 322 996.09 | 75 919.79 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.